Cargando…
Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
Background. Doxorubicin/ifosfamide is a first-line systemic chemotherapy for the majority of advanced soft tissue sarcoma (ASTS) subtypes. Trabectedin is indicated for the treatment of ASTS after failure of anthracyclines and/or ifosfamide; however it is being increasingly used off-label as a first-...
Autores principales: | Guest, Julian F., Panca, Monica, Sladkevicius, Erikas, Gough, Nicholas, Linch, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835776/ https://www.ncbi.nlm.nih.gov/pubmed/24302852 http://dx.doi.org/10.1155/2013/725305 |
Ejemplares similares
-
Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom
por: Guest, Julian F., et al.
Publicado: (2013) -
Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients
por: Verboom, Michiel C., et al.
Publicado: (2019) -
Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter
por: Dang, Jing-Yi, et al.
Publicado: (2022) -
Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015) -
Trabectedin for soft tissue sarcoma
Publicado: (2021)